Enterprise Pharmacy Forward

Clinical Pharmacy

One year of CAR-T therapy: Advancing personalized cancer treatment at Geisinger

Authors: Lori Stopper, RPh, PharmD, Kayla Aufiero, RPh, PharmD Geisinger Medical Center in Danville and the Geisinger Cancer Institute have successfully completed the first year of chimeric antigen receptor T-cell (CAR-T) therapy infusions, treating 12 patients with the goal of achieving long-term remission — or even a potential

Tenecteplase is here: Navigating the shift of a stroke thrombolytic in the United States prior to FDA approval: a mini-review on rationale, barriers and pathways

Authors: Julian M. Burwell, Jason R. Howay, Lisa Wasko, Samantha Doucoure, Jamie L. Kerestes, Clemens M. Schirmer, David Ermak, Anthony Noto, Philipp Hendrix Until March 2025, alteplase (TPA) was the sole thrombolytic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke

Expanding behavioral health pharmacy services through the Geisinger–Acadia Partnership

Author: Brian Simpkins In 2023, Geisinger and Acadia Healthcare launched a joint venture to expand behavioral health services across the Geisinger service region. The partnership began with the opening of Geisinger Behavioral Health Northeast in Moosic, Pa., followed by the launch of a second facility in Danville in August 2025.

Ambient documentation: Improving the Medication Therapy Disease Management pharmacist’s productivity by decreasing documentation time

Authors: Anthony Olson, Leeann Webster, Stacey Grassi and Duncan Dobbins productivity by decreasing d Authors: Anthony Olson, Leeann Webster, S Geisinger’s Medication Therapy Disease Management (MTDM) clinical pharmacists devote a sizable share of each workday to documenting notes for their clinical encounters in the electronic health record (EHR). The

Expanding clinical impact: Specialty MTDM’s role in collaborative, patient-centered care

Authors: Susanne Burns, Amanda Popko, Allyson Hess and Allison Cebulko Specialty MTDM continues to expand its clinical footprint through innovative partnerships and interdisciplinary care models that enhance patient access, optimize therapy and improve outcomes across a growing number of specialties. These initiatives demonstrate the critical role of pharmacists in advancing

Balancing demand and evidence: MTDM’s oversight of GLP-1 prescribing

Authors: Susanne Burns, Amanda Popko and Allison Cebulko In response to the rising cost and growing demand for GLP-1 receptor agonists, Specialty MTDM, in collaboration with the Value & Strategy team, implemented a systemwide initiative designed to make sure prescribing practices remain clinically appropriate and financially sustainable. GLP-1